Neuralstem (CUR) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Neuralstem (CUR) PT Cut to $4 at Brean Capital, 'Buy' Maintained
August 12, 2016 9:51 AM EDTBrean Capital analyst Jonathan Aschoff lowered his price target on Neuralstem (NASDAQ: CUR) to $4.00 (from $8.00) following Q2 results but maintained a Buy rating as cost savings plan is in place and as the 189 trial is enrolling.
Aschoff commented, "Neuralstem continues to enroll patients into the multi-site Phase 2 trial (n=220) with... More
